Holger F. Hebart

Holger F. Hebart

Mutlangen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 17, 2026

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Journal: Leukemia

Published: October 30, 2025

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 27, 2024

Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

Journal: Vaccines

Published: September 24, 2024

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Journal: Blood

Published: September 17, 2024

Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer.

Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer.

Journal: Oncology research and treatment

Published: August 01, 2024

Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing.

Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing.

Journal: The Journal of allergy and clinical immunology

Published: September 21, 2023

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.

Journal: Leukemia

Published: September 14, 2023

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: May 10, 2023

Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome.

Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome.

Journal: The Journal of allergy and clinical immunology

Published: March 23, 2023

Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.

Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.

Journal: ESMO open

Published: January 23, 2023

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

Journal: Blood

Published: January 17, 2023

Showing 1-12 of 40

Last Updated: 09/26/2026